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Abstract
Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons. Safety concerns
with the currently available smallpox vaccine indicate a need for research on alternative poxvirus vaccine strategies.Molecular vaccines involving the
use of proteins and/or genes and recombinant antibodies are among the strategies under current investigation. The poxvirus L1 protein, encoded by
the L1R open reading frame, is the target of neutralizing antibodies and has been successfully used as a component of both protein subunit and DNA
vaccines. L1-specific monoclonal antibodies (e.g., mousemonoclonal antibodymAb-7D11,mAb-10F5) with potent neutralizing activity bind L1 in a
conformation-specific manner. This suggests that proper folding of the L1 protein used in molecular vaccines will affect the production of
neutralizing antibodies and protection. Here, we co-crystallized the Fab fragment of mAb-7D11 with the L1 protein. The crystal structure of the
complex between Fab-7D11 and L1 reveals the basis for the conformation-specific binding as recognition of a discontinuous epitope containing two
loops that are held together by a disulfide bond. The structure of this important conformational epitope of L1 will contribute to the development of
molecular poxvirus vaccines and also provides a novel target for anti-poxvirus drugs. In addition, the sequence and structure of Fab-7D11 will
contribute to the development of L1-targeted immunotherapeutics.
Published by Elsevier Inc.Keywords: Conformational epitope; Vaccinia; Poxvirus L1R; Neutralizing antibody; Fab structureIntroduction
As a result of potential bioterrorism threats from smallpox
(caused by Variola virus), there has been renewed interest in
poxvirus vaccines and protective immunity (Harrison et al.,
2004). Current vaccines against smallpox require inoculation
with the related live vaccinia virus (VACV). The infection
associated with the live virus vaccine can lead to complications
in healthy individuals, but immune-deficient individuals and
pregnant women are at special risk (Henderson et al., 1999;⁎ Corresponding author. Fax: +1 301 402 0284.
E-mail address: dgarboczi@niaid.nih.gov (D.N. Garboczi).
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2 Present address: Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA
19486, USA.
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2007.06.042Belongia and Naleway, 2003). One current approach to improve
the vaccination strategy is to use viral strains that are more
attenuated (Coulibaly et al., 2005; Kidokoro et al., 2005). An
alternative is to use viral protein subunits and/or genes in a
molecular vaccine approach.
Development of molecular vaccines requires the identifica-
tion of poxvirus immunogens that elicit immune responses
contributing to protection (Galmiche et al., 1999; Hooper et al.,
2000; Fogg et al., 2004; Davies et al., 2005; Sakhatskyy et al.,
2006). Several protective immunogens have been identified,
including the poxvirus L1 protein encoded by the L1R open
reading frame. L1-based DNA vaccines and protein subunit
vaccines can elicit neutralizing antibodies in mice and nonhu-
man primates and contribute to protection in lethal disease
models (Fogg et al., 2004; Hooper et al., 2004; Heraud et al.,
2006; Xiao et al., 2007).
Fig. 1. Interaction of mAb-7D11, F(ab′)2, and Fab fragments with purified
VACV and recombinant L1. (A) Binding to purified VACV. Serial twofold
dilutions of mAb-7D11, 7D11-F(ab′)2, and 7D11-Fab or negative control anti-
body mAb-3D7 starting at 80 μg/ml were tested for the capacity to bind purified
virus by VACV-infected-cell lysate ELISA. Some antigen-coated plates were
treated with UV light (grey dashed lines) before incubation with mAb-7D11
(MAb-7D11 UV). Each symbol represents the mean±standard deviation (SD) of
duplicate samples. (B) Binding to recombinant L1. Serial twofold dilutions of
mAb-7D11, 7D11-F(ab′)2, and 7D11-Fab or negative control antibody mAb-
10F10 (anti-A33) starting at 80 μg/ml were tested for the capacity to bind recom-
binant L1 by ELISA. Purified L1 at 100 ng/well was untreated or treated with UV
light (grey dashed lines). Each symbol represents the mean±SD of duplicate
samples. The x-axes in panels A and B are plotted on log(2) scales. The smallest
error bars in panels A and B are hidden beneath the symbols and are not seen.
332 H.-P. Su et al. / Virology 368 (2007) 331–341L1 is a myristoylated, transmembrane protein found on the
surface of themature virion (MV) form of poxviruses (Ravanello
et al., 1993). It is conserved in all orthopoxviruses and its
sequence is almost identical among VACV, Variola virus, and
monkeypox virus. Deleting the L1R gene blocks morphogenesis
and prevents the formation of infectious virus (Ravanello and
Hruby, 1994). However, L1 may also play a role (direct or
indirect) in viral entry into cells because L1-specific monoclonal
antibodies (e.g., mouse monoclonal antibodies: 7D11, 10F5, and
2D5) bind the surface of the virions and efficiently neutralize
infectivity (Wolffe et al., 1995; Ichihashi and Oie, 1996; Hooper
et al., 2000). These antibodies neutralize infectivity after virion
attachment (Ichihashi et al., 1994; Wolffe et al., 1995); however,
recent reports indicate that the L1 protein is not a component of
the viral fusion complex (Senkevich et al., 2005; Townsley et al.,
2005; Moss, 2006). L1 contains three disulfide bonds, which are
formed by the virus-encoded redox pathway (Senkevich et al.,
2002). Two of the three intramolecular disulphide bonds are
essential for production of infectious viral particles (Blouch et
al., 2005). When the bonds in L1 are reduced, the neutralizing
antibodies, mAb-7D11, mAb-10F5 and 2D5, cannot recognize
L1 (Wolffe et al., 1995; Ichihashi and Oie, 1996), (Hooper, J.W.,
Schmaljohn, A.L., unpublished data). Because L1 is an
attractive candidate for potential subunit vaccines and/or
immunotherapeutics it is important to understand the nature of
the epitopes of L1 that play a crucial role in antibody-mediated
protective immunity. In this report, we investigated the nature of
the interaction between mAb-7D11 and L1 and the mechanism
by which these potent neutralizing antibodies prevent infection.
The co-crystal structure of the Fab fragment of 7D11 bound to
the L1 protein reveals the basis for the conformation-specific
binding as recognition of a discontinuous epitope containing two
loops held together by a disulfide bond.
Results
MAb-7D11, 7D11-F(ab′)2, and 7D11-Fab fragments bind
purified VACV and recombinant L1 expressed in Escherichia
coli
Before performing co-crystallization studies involving re-
combinant L1 and 7D11-Fab, we tested the differential capacity
of mAb-7D11, 7D11-F(ab′)2, and 7D11-Fab to bind VACVand
recombinant L1 purified from E. coli. Purified mAb-7D11,
7D11-F(ab′)2, and 7D11-Fab were evaluated for binding on
ELISA plates coated with purified VACV (Fig. 1A). MAb-7D11
and 7D11-F(ab′)2 bound the purified viral antigen at all
concentrations tested. In contrast, 7D11-Fab only bound to
purified virions when the Fab concentration was high. We ob-
served similar ELISA results using recombinant L1 purified
from E. coli as antigen (Fig. 1B). Interestingly, when the purified
VACV or recombinant L1 was treated with ultraviolet (UV)
light, reactivity with mAb-7D11, 7D11-F(ab′)2, and 7D11-Fab
was lost (Figs. 1A and B). Thus, 7D11-Fab bound both intact
virions and recombinant L1 protein albeit with lower reactivity
than bivalent forms of the antibody, and the epitope recognized
by this antibody could be disrupted when exposed to UV light.Neutralization capacity of mAb-7D11, 7D11-F(ab′)2, and
7D11-Fab fragments
We investigated the ability of mAb-7D11, 7D11-F(ab′)2, and
7D11-Fab fragments to neutralize VACV infection by a plaque
reduction–neutralization test (PRNT) (Fig. 2A). As expected,
mAb-7D11 efficiently neutralized VACV plaque formation as
previously described (Wolffe et al., 1995). 7D11-F(ab′)2
fragments were also able to neutralize VACV plaque formation
to levels similar to those of the intact immunoglobulin. Even at
0.04 μg/ml, the lowest concentration tested, 7D11-F(ab′)2
yielded ∼75% neutralization. In contrast, 7D11-Fab required
more than 100× greater concentrations of protein to give a
similar level of neutralization. At the highest concentration used,
80 μg/ml, Fab fragments elicited ∼75% reduction in plaque
number. These findings indicated that bivalency plays a role in
the capacity of mAb-7D11 to efficiently neutralize VACV.
Fig. 2. Plaque reduction-neutralization test using mAb-7D11, 7D11-F(ab′)2, and
7D11-Fab. (A) VACVwas incubated with purified mAb-7D11, 7D11-F(ab′)2, or
7D11-Fab at 37 °C for 1 h. Virus–antibody mixtures or untreated virus were
adsorbed on to confluent monolayers of BSC-1 cells, followed the addition of a
semi-solid overlay of 1.5% methylcellulose as described in Materials and
methods. After 4 days, plaques were counted after stainingwith 3% crystal violet.
The percent neutralization of plaque formation by antibody addition relative to
untreated virus is plotted versus concentration on a log(2) scale. (B) VACV was
incubatedwith mAb-7D11 or 7D11-Fab at the concentrations indicated, for 1 h at
37 °C. One sample, incubated with Fab, was then incubated with anti-Fab
antibodies (1:100) for 1 h. The other samples were incubated for an additional 1 h
in the absence of anti-Fab antibodies. After incubation, the virus was added to
BSC-1 cells and plaque formation analyzed as described in panel A. (C)
Confluent monolayers of BSC-1 cells were chilled on ice and incubated with
∼50 PFU of VACV strain IHD-J per well for 1 h at 4 °C. After adsorption, virus
was removed andmAb-7D11 or 7D11-Fabwas added to the wells at the indicated
concentrations for 1 h at 4 °C. After incubation, anti-Fab antibodies (1:100) were
added to the wells of some samples for another 1 h at 4 °C. Plates were then
incubated at 37 °C and plaques were visualized as described in panel A.
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neutralizing activity, we incubated 7D11-Fab fragments with
VACV, added anti-Fab antibody, and assayed neutralization by
the PRNT. As shown in Fig. 2B, incubating 7D11-Fab with anti-
Fab antibodies restored neutralizing activity. This finding
confirmed that bivalency does indeed play a key role in the
ability of mAb-7D11 to neutralize.The role of bivalency in the enhancement of 7D11-mediated
neutralization could be due to intra- and/or inter-particle (aggre-
gation) cross-linking. To investigate this, 50 PFU of VACVwere
adsorbed onto BSC-1 cell monolayers at 4 °C. Since only
50 PFU of VACV were used, we reasoned that the viral particles
were not close enough to permit inter-particle interactions and
therefore allowed us to determine how much neutralization was
due to intra-particle L1 binding. Following adsorption, unbound
virus was removed and bound particles were incubated at 4 °C
with varying concentrations of either mAb-7D11 or 7D11-Fab.
Subsequently, anti-Fab antibodies were added to the mono-
layers. Plaque formation was analyzed 4 days post-infection. As
predicted, mAb-7D11 efficiently neutralized VACV plaque
formation when added post-adsorption (Fig. 2C). 7D11-Fab
alone neutralized virus poorly, and even at the highest
concentration tested, only ∼50% of virus was inhibited.
Cross-linking of the 7D11-Fab fragments bound to adsorbed
virus led to a marked increase in virus neutralization, albeit less
efficiently than that of mAb-7D11. The neutralizing effect of
7D11-Fab plus anti-Fab antibodies was rapidly lost as the
concentration of Fab fragments was reduced, possibly due to the
inefficient binding of 7D11-Fab to L1 at 4 °C. That cross-linked
7D11-Fab was capable of neutralizing VACV suggested that a
significant portion of the bivalent neutralizing capability of
mAb-7D11 is intra-particle L1 binding.
The structure of the complex between L1 and 7D11-Fab
To understand the basis of the conformational specificity of
mAb-7D11 recognition, the structure of the complex between
7D11-Fab and L1 was determined by X-ray crystallography
(Table 1). Four copies of the Fab/L1 complex were present in the
crystal asymmetric unit. The 7D11-Fab bound to a surface on L1
formed by four long loops on the side of the molecule opposite
the amino and carboxyl termini of L1 and presumably away from
the viral membrane. These four loops connect the helices of the
helical bundle to the strands of the beta sheets of L1 (Fig. 3A).
The heavy chain of 7D11-Fab comprised most of the recognition
site for L1 (Fig. 3B). A total surface area of 1340 Å2 was buried
in the interface between the heavy chain and L1, in contrast to the
225 Å2 of buried surface area in the light chain:L1 interaction.
The typical range for total surface area buried at the interface
between an antigen and both chains of the antibody is 1400–
1700 Å2 (Davies et al., 1990). Another measure that qualita-
tively describes the strength of the interaction is the analysis of
the interaction surface as given by the shape complementarity
statistic (Sc), where a perfect fit yields a score of 1 (Lawrence
and Colman, 1993). The heavy chain:L1 interface gave a Sc of
0.65, which is within the range (0.64–0.68) for antibody:antigen
complexes. The light chain:L1 interface only yielded a score of
0.26, indicating poor complementarity with L1.
Analysis of the molecular interactions between 7D11-Fab
and L1 also confirmed that the light chain does not significantly
contribute to binding. In the structure, there were no interactions
between the light chain and L1 within a distance of 4 Å. In
contrast, there were hydrogen bonds (Table 2) formed by the
antibody to residues of loops 1 and 2 of L1. These loops are held
Fig. 3. Structure of 7D11-Fab bound to L1. (A) 7D11-Fab recognizes the loops
connecting the helices to the β strands of L1. The ribbon diagram shows L1
bound by the 7D11-Fab (gray). L1 is colored by secondary structure with β
sheets in red, helices in blue, and loops in green. Disulfide bonds are shown in
yellow. (B) The heavy chain of 7D11-Fab provides most of the interactions with
L1. In the same orientation as in A, the surface diagram is colored by polypeptide
chains with the 7D11 heavy chain in orange, the light chain in green, and L1 in
blue. The calculated total buried surface area and the shape complementarity
statistic between L1 and each of the antibody chains are indicated. (C) 7D11-Fab
makes numerous hydrogen bonds and van der Waals interactions with loops 1
and 2 of L1. Oriented as in parts A and B, and numbered from N-terminus to C-
terminus, the four loops of L1 are colored as follows: loop 1 (green), loop 2
(blue), loop 3 (purple), and loop 4 (brown). These loops are held together by a
disulfide bond (yellow) between Cys 34 in loop 1 and Cys 57 in loop 2. The
carbon atoms are colored based on the loop that the residue is in, nitrogen atoms
are blue, and oxygen atoms are red. Hydrogen bonds displayed as dashed lines in
blue show extensive bonding with loop 1 (green) and loop 2 (blue) of L1.
Table 1
Crystallographic statistics
Resolution (Å) 50–3.10 (3.21–3.10)
X-ray source 19-ID SBC-CAT
Energy (eV) 12662
Wavelength (Å) 0.97915
Completeness (%) 98.6 (99.6)
Average redundancy 3.2 (3.2)
Rsym (%) 12.4 (46.4)
bIN/bσIN 9.3 (2.3)
Dimensions of C2 cell
a (Å) 218.8
b (Å) 85.6
c (Å) 211.8
α (°) 90
β (°) 119.60
γ (°) 90
Ramachandran
Favored 83.4%
Allowed 15.6%
Generously allowed 1.0%
Disallowed 0.0%
Rmsd bond lengths 0.01 Å
Rmsd bond angles 1.4°
No. of residues 2466
No. of protein atoms 18612
No. of water 14
No. of glycerols 8
No. refl. refined/no. free 58119/3109
Rwork/Rfree (%) 23.8 (32.3)/25.4 (35.7)
Values in parenthesis are for the highest resolution bin.
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of loop 2 (Fig. 3C). There were also additional van der Waals
interactions between the heavy chain and loops 1–3 of L1
(Table 3). The loops and residues of L1 which mediate inter-
actions with 7D11 are mapped on the L1 sequence in Fig. 4C.
mAb-7D11, but not mAb-10F5, binds the 2D5 escape mutant
Previous studies reported the isolation of a mutant VACV that
escaped neutralization by the L1-specific mouse mAb, 2D5
(Ichihashi and Oie, 1996). The escape mutation was in the L1R
gene and resulted in a change in residue 35 from an Asp to an
Asn (D35N). Because mAb-7D11 binds to a similar epitope as
2D5, we wanted to determine if a change from an Asp to Asn
would disrupt mAb-7D11 binding. COS-7 cells were transfected
with either pWRG/TPA-L1R or a plasmid containing the D35N
mutation. pWRG/TPA-L1R is a plasmid in which the tissue
plasminogen activator (TPA) secretion signal sequence is
inserted upstream and in-frame with the L1R open reading
frame. The TPA permits L1 to be processed through the endo-
plasmic reticulum where it can take advantage of the
endogenous cellular disulfide bond formation machinery and
fold properly. Because the transmembrane region was not
removed, the molecule was targeted to the plasma membrane
where it could be detected by anti-L1 antibodies (Hooper et al.,
2007). At 48 h post-transfection, the ability of antibodies to bind
to surface-expressed L1 or L1 D35N was examined by flow
cytometry (Fig. 4A). As indicated by the shift in fluorescence
intensity, mAb-7D11 interacted with both L1 and the D35Nmutant. In contrast, a second L1-specific mAb with potent
neutralizing activity, mAb-10F5, did not efficiently interact with
the L1 D35N molecule. Neither mAb-7D11 nor mAb-10F5
interacted with cells transfected with the empty pWRG vector.
MAb-7D11 and mAb-10F5 competed for binding to VACV as
measured by competition ELISA (Hooper, J.W., Schmaljohn,
A.L., unpublished observations). As a control, we used an anti-
Table 2
Hydrogen bonds between L1 and 7D11-Fab
From L1 To HC Distance
Residue
name
Atom Loop Residue
name
Atom CDR
Lys 33 N 1 Asp 102 O 3 2.7 Å
Asp 35 Oδ1 1 Tyr 50 OH 2 2.9 Å
Asp 35 Oδ1 1 Trp 33 Nε1 1 3.0 Å
Asp 35 Oδ2 1 Trp 33 Nε1 1 3.3 Å
Asp 35 Oδ2 1 Asn 52 Nδ2 2 3.1 Å
Ala 59 O 2 Asn 52 Nδ2 2 2.9 Å
Asp 60 N 2 Thr 30 O 1 3.6 Å
Asp 60 Oδ1 2 Ser 54 Oγ 2 3.4 Å
Asp 60 Oδ2 2 Arg 31 Nε 1 3.4 Å
Asp 60 Oδ2 2 Thr 30 Oγ1 1 2.9 Å
Listed are the atoms from L1 and their corresponding loops, the hydrogen bond
partner in the heavy chain (HC) and their corresponding complementarity-
determining region (CDR) loop, and the distances between them.
Table 3
Van der Waals interactions between L1 and the heavy chain of 7D11-Fab
L1 Loop HC CDR
Asn 27 1 Arg 31 1
Gln 31 1 Asp 102 3
Gln 31 1 Tyr 104 3
Thr 32 1 Asp 102 3
Thr 32 1 Trp 33 1
Thr 32 1 Tyr 104 3
Lys 33 1 Asp 102 3
Lys 33 1 Trp 33 1
Lys 33 1 Tyr 104 3
Asp 35 1 Asn 52 2
Asp 35 1 Trp 33 1
Asp 35 1 Tyr 50 2
Asp 35 1 Tyr 57 2
Ser 58 2 Trp 33 1
Ala 59 2 Asn 52 2
Ala 59 2 Ser 54 2
Ala 59 2 Thr 30 1
Ala 59 2 Trp 33 1
Asp 60 2 Arg 31 1
Asp 60 2 Ser 54 2
Asp 60 2 Thr 30 1
Ala 61 2 Ser 54 2
Ala 61 2 Thr 55 2
Asp 62 2 Ser 54 2
Lys 125 3 Gly 56 2
Lys 125 3 Thr 58 2
Lys 125 3 Tyr 57 2
Lys 127 3 Tyr 57 2
Residues that participate in van der Waals interactions (4 Å distance cutoff)
between L1 and 7D11-Fab are shown. Listed on the left are the atoms from L1
and their corresponding loops. On the right are the interacting atoms in the heavy
chain (HC) and their corresponding complementarity-determining region (CDR)
loop.
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interact with L1-expressing cells (Fig. 4A). These observations
indicated that mutation of Asp35 to Asn did not disrupt the
interaction of all potent neutralizing L1-specific monoclonal
antibodies even if they bound the same region of L1 as measured
by competition ELISA.
Structural basis for the binding of mAb-7D11 to a
neutralization escape mutation in L1
In the 7D11-Fab structure, Asp35 is involved in hydrogen
bonds with the mAb-7D11 heavy chain. Based on the distances
between atoms capable of forming hydrogen bonds (Table 2),
the Oδ1 atom of Asp35 can form a hydrogen bond with Tyr50 on
the heavy chain, while Oδ2 of Asp35 can form a hydrogen bond
with the Nε1 atom of Trp33 on the heavy chain (Fig. 4B, top). If
Asp35 was changed to Asn, the hydrogen bondwith Tyr50 could
still occur (Fig. 4B, bottom). The hydrogen bond formed by Oδ2
of Asp35 with Trp33 could be replaced by a similar hydrogen
bond between Nδ2 of Asn35 and Oδ2 of an alternative Asn52
rotamer conformation on the heavy chain. The hydrogen bond
made by Asn52 of the heavy chain to the carbonyl oxygen of
Ala59 in L1 can still be formed by the alternate rotamer (Fig. 4B,
bottom). Thus, based on the structure of the complex, we can
provide an explanation for the binding of mAb-7D11 to the
D35N mutant, while other L1-specific antibodies (2D5 and
mAb-10F5) may not accommodate the hydrogen bond with Nδ2
of Asn35 of the D35N escape mutant.
Discussion
In this study, we characterized the binding of mAb-7D11, a
potent neutralizing antibody that recognizes L1 on the surface of
poxvirus virions. The 7D11-Fab:L1 co-crystal structure reveals
interactions to loops 1 and 2 of L1 that are held together by a
disulfide bond between Cys34 and Cys57. The conformations of
the loops are stabilized by the disulfide bond, which provides the
explanation at the molecular level for previous reports that the
7D11 epitope is disrupted by disulfide bond reduction.A panel of six anti-L1 antibodies was recently characterized
(Aldaz-Carroll et al., 2005). Peptide mapping and blocking
assays demonstrated that the mAbs bound two different
antigenic sites. Two of the antibodies (VMC-4 and VMC-35)
bound a conformational epitope andwere non-neutralizing. Four
of the antibodies (VMC-2, VMC-3, VMC-5, VMC-6) recog-
nized a linear, or pseudolinear, epitope, which includes residues
118–128 of L1 and were neutralizing (Aldaz-Carroll et al.,
2005). In blocking experiments, none of the six mAbs bound to
the same conformational epitope recognized by the neutralizing
antibodies 7D11, 2D5, and 10F5. MAb-7D11 and mAb-2D5
compete for binding to L1 as measured by BIAcore (Aldaz-
Carroll et al., 2005) and mAb-7D11 and mAb-10F5 bind to the
same site by competition ELISA. The 7D11:L1 co-crystal
structure reveals that there is some overlap between the linear
neutralizing epitope that includes residues 118–128 of L1 and
the conformational epitope recognized by mAb-7D11. Two
residues of loop 3 of L1 (loop 3 is colored purple in Figs. 3C and
4B), Lys125 and Lys127, make van der Waals contacts with
mAb-7D11 (Table 3) and are also contained within the linear
epitope mapped to antibodies generated by Aldaz-Carroll et al.;
however, it is possible that Lys125 and Lys127 do not contribute
significantly to mAb-7D11 binding which would allow mAb-
7D11 and other antibodies to bind simultaneously. This structure
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surface made by the loops at the end of L1 is accessible to
antibody and that binding of antibody to this region of L1
interferes with events involved in entry.
None of the six L1-specific mAb characterized by Aldaz-
Carroll et al. bind the same epitope recognized by the highly
potent neutralizing mAb-7D11. The six antibodies were gene-
rated by immunizing mice with the ectodomain of L1 producedFig. 4. Interaction of anti-L1 monoclonal antibodies with mutated L1. (A) COS-7 ce
(grey line), or empty pWRG vector (solid grey). Cells were incubated with 1:100 dilu
10F10 (anti-A33). An anti-mouse secondary antibody (1:500) conjugated to Alexa 4
FACSCalibur flow cytometer. For each sample, 10000 cells were counted. (B) Hydrog
in the crystal structure are shown in blue. The atoms of critical residues are shown as s
(green), loop 2 (blue), loop 3 (purple), and loop 4 (brown). In the structure (upper p
Tyr50 on the heavy chain (gray). Also shown is the hydrogen bond between the carbo
the lower panel, the predicted binding of mAb-7D11 to the D35N mutant of L1 (Mod
heavy chain would be analogous to the bond made with Asp35. A new hydrogen bon
the Fab heavy chain, while maintaining the hydrogen bond (red) between Ala59 of L1
around the vertical axis relative to its orientation in Fig. 3C. (C) Alignment of the L1 e
residues are shown that differ from the vaccinia virus sequence. Residues of the four
loop 4 (brown). Residues involved in van der Waals interactions are marked with on
above the sequence. Cysteines are highlighted in yellow.in the baculovirus expression system, while mAb-7D11 was
generated by vaccinating with infectious virus. The baculovirus-
expressed L1 protein was targeted through the endoplasmic
reticulum for secretion by the addition of a melittin signal
peptide to L1 and appears to be folded correctly as measured by
the binding of mAb-7D11 and the presence of three disulfide
bonds. Glycosylation, however, is present in the baculovirus-
produced protein, unlike the L1 produced in a VACV-infectedlls were transfected with pWRG/TPA-L1R (black line), pWRG/TPA-L1R D35N
tions of mAb-7D11 (anti-L1), mAb-10F5 (anti-L1), or a control antibody mAb-
88 fluorochrome was added and cells were analyzed by flow cytometry using a
en bonds involved in the binding by the 7D11-Fab to Asp35 of L1 as determined
ticks. The carbon atoms retain the color of the loops to which they belong: loop 1
anel), Asp35 (green) makes hydrogen bonds with the side chains of Trp33 and
nyl oxygen of Ala59 on L1 (blue) and Nδ2 of Asn52 of the heavy chain (gray). In
el) is shown. The hydrogen bond between Asn35 of L1 (green) and Tyr50 of the
d (red) can be formed between Asn35 of L1 and an alternate rotamer of Asn52 of
and Asn52 of the heavy chain. The L1:7D11-Fab structure has been rotated 180°
ctodomain sequences from VACV, Variola virus, and monkeypox virus in which
loops are shaded as in Fig. 3C: loop 1 (green), loop 2 (blue), loop 3 (purple), and
e dot and residues that also mediate hydrogen bonds are marked with two dots
337H.-P. Su et al. / Virology 368 (2007) 331–341cell, which does not translocate to the cellular compartments that
possess glycosylation machinery. Asn residues 27, 50, and 117
are possible N-linked sites and Asn50 and Asn117 were shown
to be glycosylated (Aldaz-Carroll et al., 2005). A glycan on
Asn27 could alter the immunogenicity of this epitope as Asn27
makes van der Waals contacts with the 7D11-Fab (Table 2). We
found that the correct conformation of the 7D11 epitope can be
disrupted by UV light. Exposure of VACV-infected cell lysate or
purified L1 protein to UV light ablated binding of mAb-7D11
(Fig. 1) or mAb-10F5 (data not shown). UV radiation likely
disrupted the critical disulfide bonds required for generating
high-affinity neutralizing epitopes as it is well known that UV
light can break disulfide bonds, especially through the photo-
excitation of aromatic residues (Neves-Petersen et al., 2006;
Vanhooren et al., 2006). In the past, UV-killed poxvirus vaccines
were tested for the capacity to protect (Turner et al., 1970). In
retrospect, our data indicate that UV-inactivated poxvirus
antigen lacks an important L1-neutralizing epitope. These data
emphasize the importance of vaccination with an intact,
correctly folded, and processed protein, to provide the
discontinuous epitope formed by the loops of L1.
MAb-7D11, 7D11-F(ab′)2, and cross-linked 7D11-Fab
exhibit exceedingly potent neutralizing activity, even when
added after virus adsorption to cell monolayers. In addition,
passive transfer experiments in mice indicate this mAb can elicit
protective immunity (Hooper et al., 2002; Lustig et al., 2005).
The mechanism by which mAb-7D11 neutralizes virus remains
unknown. Here, we identified the precise region of the poxvirus
that mAb-7D11 binds and we demonstrated that bivalent
binding enhanced the neutralizing activity of this antibody. The
ability of high Fab concentration to neutralize virus suggests
that the effect does not absolutely require cross-linking of L1 on
the surface of virions. The reduced interaction of 7D11-Fabs
with intact VACV (Fig. 1A) and purified L1 (Fig. 1B) suggest
that the poor neutralizing capacity of 7D11-Fabs was largely
due to avidity. This reduced capacity of Fab to neutralize VACV
was reported for L1-specific 10F5-Fab (Schmaljohn et al.,
1999). Our findings are similar to what has been reported with
7–10A, a mAb that interacts with a discontinuous epitope
present in the spike protein of murine hepatitis virus (MHV)
(Lamarre and Talbot, 1995). In that study, bivalency signifi-
cantly enhanced neutralization of MHV both in vitro and in
vivo; however, Fab fragments could also neutralize virus but to a
much lesser extent. The authors concluded that bivalency might
enhance neutralization by steric hindrance or by causing a
conformational change in the viral protein due to the increased
avidity. It is possible that mAb-7D11 functions by sterically
hindering the interaction of L1 with viral or cellular molecules
or by blocking a conformational change in the virion required
for entry. Further studies will be required to identify the critical
step in the infection process blocked by mAb-7D11 and other
mAbs binding the same epitope on L1. Post-attachment steps
that could be targeted by these mAbs include: the triggering
of host-cell signaling pathways involved in particle uptake,
the activation or function of the viral fusion complex, or the
uncoating events required to deliver active viral replication
machinery to the cytoplasm.The L1:7D11-Fab complex structure provides details of the
molecular interactions made by mAb-7D11. With its heavy and
light chains sequenced and the specific interacting residues thus
mapped, mAb-7D11 can be humanized for development as a
therapeutic. The appropriate human antibody scaffold may be
found by comparing root mean square deviations (rmsd) of
known human antibody structures with mAb-7D11. This could
minimize the positional changes of the interacting loops after
engineering 7D11 to be like a human immunoglobulin. With the
mapped interactions, the specificity-determining residues can
also be used to minimize human anti-murine antibody responses
(Padlan et al., 1995; Kashmiri et al., 2005).
With knowledge of the molecular interactions, mutations can
be made to enhance mAb-7D11 binding. Molecular modeling
may determine mutations in mAb-7D11 that would strengthen
its interactions with L1. The affinity of mAb-7D11 can also be
improved by experimental, molecular techniques such as phage
display. Because the wild-type mAb-7D11 light chain does not
contribute significantly to binding L1, it may be possible to
identify light chain mutations that increase the affinity of mAb-
7D11. Although the epitopes of 2D5, mAb-10F5, and mAb-
7D11 overlap, there are differences in their binding to the D35N
mutant of L1. Thus, combinations of L1-specific mAb would
likely neutralize antibody escape mutants should they arise.
In the crystal that was used to determine the structure of L1
alone, two L1 molecules packed together in the asymmetric unit
(Su et al., 2005). While others and we observed only monomeric
L1 in solution (Aldaz-Carroll et al., 2005), the same packing was
observed in the independently derived 7D11-Fab and L1
complex crystal of this study. Two sets of L1 pairs packed in
the same manner as in the crystal of L1 alone. One pair of L1
molecules had an rmsd of 1.2 Å and the other pair exhibited an
rmsd of 1.3 Å, calculated using 339 Cα−Cα distances (out of
346). If this dimer is physiologically relevant, the complex
structure indicates that the same antibody molecule could not
bind the two L1 molecules, as the two Fabs bound to each pair of
L1molecules are oriented in opposite directions. More work will
be required to determine the exact orientation of L1 on the
surface of virions. There are neutralizing anti-L1 antibodies that
do not block binding by mAb-7D11 (Aldaz-Carroll et al., 2005).
This suggests the interesting possibility that a bi-specific
antibody consisting of mAb-7D11 and another specificity that
does not block mAb-7D11 may together bind L1 and potentially
exhibit a greater neutralizing activity.
Future work will seek to humanize the mAb-7D11 antibody
either in the context of a mono-specific or bi-specific construct.
Such a molecule used in conjunction with other humanized
antibodies that target enveloped particles, such as the humanized
chimpanzee B5 antibodies (Chen et al., 2006), may serve as a
replacement for vaccinia immune globulin and can be used to
treat sequelae arising in individuals vaccinated with live-virus.
Alternatively, such a cocktail might function as a standalone
anti-poxvirus therapeutic.
Lastly, based on the crystal structure of the mAb-7D11 com-
plex, we identified a critical region on an essential, highly
conserved poxvirus protein. Our data indicate that binding of
Fab to this region (albeit at high concentrations) can neutralize
338 H.-P. Su et al. / Virology 368 (2007) 331–341virus infectivity. It will be possible to model the binding of other
compounds to this structure and, in doing so, develop candidate
antiviral drugs that may efficiently neutralize virus in serum. If
such a compound could cross the cell membrane, it might be
possible to neutralize infectivity during morphogenesis and
prevent infectious virus from being released and disseminated.
Materials and methods
Cells and virus
BSC-1, VERO and COS-7 cells were maintained as mono-
layers in Eagle's minimal essential medium (EMEM) supple-
mented to contain 5% (v/v) fetal calf serum (Hyclone; Logan,
UT), 10 mM HEPES, 100 U/ml penicillin, and 100 μg/ml of
streptomycin. VACV strains IHD-J and Western Reserve (WR)
were propagated on VERO monolayers and clarified crude
lysates were stored until use at −70 °C. WR was purified on a
20–60% sucrose gradient by centrifugation at 25,000×g for 2.5 h
in an SW28 rotor (Beckman, Palo Alto, CA). The WR band was
harvested from the gradient by using a glass Pasteur pipette.
Generation of mAb-7D11, 7D11-F(ab′)2, and 7D11-Fab
MAb-7D11 was obtained from culture supernatants of mAb-
7D11 hybridoma cells and purified on a mAb-Trap antibody-
binding column (Amersham Biosciences) according to the
manufacturer's protocol. 7D11-F(ab′)2 was generated using the
ImmunoPure F(ab′)2 preparation kit (Pierce, Rockford, IL)
following the manufacturer's recommended protocol. Briefly,
mAb-7D11 was concentrated to 10 mg/ml in F(ab′)2 digestion
buffer consisting of 20mM sodium acetate pH 4.5. Concentrated
mAb were then incubated overnight with immobilized pepsin at
37 °C with constant agitation. Separation of undigested mAb
from F(ab′)2 was performed on an affinity Pak protein A binding
column. To ensure undigested mAb were removed from the
F(ab′)2 preparation, the digested mAb were passed through the
column a second time. Recovered F(ab′)2 was concentrated in a
50-kDa molecular weight cut-off (MWCO) concentrator (Milli-
pore, Bedford, MA) in 10 mM Tris–Cl buffer. 7D11-Fab
fragments were generated using the Immunopure Fab prepara-
tion kit (Pierce) according to the recommended protocol.
Purified mAb-7D11 was incubated overnight at 37 °C in PBS
[pH 10?] containing immobilized papain. Undigested mAb were
separated from Fab fragments using a protein A binding column.
Fab fragments were run through the column a second time to
ensure that intact mAb-7D11 was adsorbed out of the Fab
preparation. Fab fragments were concentrated using a 10
MWCO concentrator in 10 mM Tris–Cl buffer.
ELISA
VACV-specific ELISAs were performed essentially as de-
scribed (Hooper et al., 2000). Purified VACV strain WR was
diluted 1:50 in PBS and 50 μL/well was added to the wells of a
96-well, high-binding ELISA plate (Corning, Corning, NY) and
dried overnight. “Mock” antigen was also plated. Mock antigenwas prepared by loading uninfected cell lysate onto the sucrose
gradient and harvesting the same portion of the sucrose gradient
from which the purified virus was removed. Some samples were
treated with UV light overnight at a distance of 550 cm from a
standard safety light used in laminar flow hoods. Plates were
blocked for 1 h at 37 °C with PBS containing 0.1% Tween-20
(v/v) (PBS-T) and 5% (w/v) dry milk. Serial dilutions of mAb-
7D11, 7D11-F(ab′)2, and 7D11-Fab fragments were made in
blocking buffer. Dilutions were incubated with bound VACV for
1 h at 37 °C. After incubation, plates were washed four times
with PBS-T and incubated with a peroxidase-conjugated anti-
mouse Fab-specific antibody (Sigma, St. Louis, MO) for 30 min
at 37 °C. Plates were subsequently washed four times and
100 μL of 2,2′-azinobis-3-ethylbenzthiazoline-6-sulfonic acid
(ABTS) substrate (KPL, Gaithersburg, MD) was added to each
well. Reactions were stopped by adding 100 μL of ABTS stop
solution of 5% (w/v) sodium dodecylsulfate. The optical density
(O.D.) at 405 nm was read on a Spectramax ELISA plate reader
(Molecular Devices, Sunnyvale, CA). For each dilution series,
the O.D. values from the mock antigen wells were subtracted
from the experimental values. Each sample was run in duplicate.
L1-specific ELISA was performed essentially as previously
described (Hooper et al., 2004). Purified L1 (Su et al., 2005)
diluted in 0.1 M carbonate buffer, pH 9.6, was plated at 100 ng/
well in 96-well plates. Plates were incubated at room
temperature overnight in the presence or absence of UV light
as described above. The remainder of the assay was performed as
described above.
Plaque reduction–neutralization test
Plaque reduction–neutralization tests (PRNT) were per-
formed as described previously (Hooper et al., 2000). VACV
strain IHD-J was incubated with either mAb-7D11, 7D11-F
(ab′)2, or 7D11-Fab at the indicated concentrations for 1 h at
37 °C in a total volume of 200 μL. Virus mixture (180 μL) was
then added to confluent monolayers of BSC-1 cells plated in 6-
well plates. Virus was adsorbed to cells for 1 h at 37 °C with
rocking every 15 min. After adsorption, a 1:1 mixture (2 ml) of
3.0% methylcellulose (w/v) in water and 2× Eagles' basal
medium with Earle's salts (EBME) was added to each well.
Plates were incubated for 4 days, then stained with 3% crystal
violet for 15 min and washed with water. In the indicated
conditions where anti-mouse Fab antibodies (Sigma) were
incubated with 7D11-Fab fragments, the 7D11-Fab fragments
were pre-bound to VACV for 1 h, followed by incubation with
anti-Fab antibodies (1:100) for 1 h. All experiments were per-
formed in duplicate.
Antibody treatment of pre-bound VACV
To determine if 7D11 molecules inhibited post-attachment
events in VACVentry, 50 plaque-forming units (PFU) of VACV
were adsorbed to BSC-1 monolayers plated in 6-well plates at
4 °C. After 1 h, unbound virus was removed by aspiration and
cells were washed once with PBS. Adsorbed virus was next
incubated with the indicated concentrations of mAb-7D11 or
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of 7D11-Fab was incubated with anti-Fab antibodies (1:100) for
1 h at 4 °C.MAb-7D11 and 7D11-Fab wells were incubated with
an equivalent volume of PBS. After 1 h, 1.5% methylcellulose
was added to each well and the plates were incubated at 37 °C for
4 days. Plates were stained as described for PRNT. Each sample
was tested in duplicate.
Site-directed mutagenesis of L1R
The pWRG/TPA-L1R plasmid has been described elsewhere
(Hooper et al., 2003). The missense mutation changing the Asp
at position 35 to an Asn was introduced into the L1R by
performing two separate PCR steps. The first reaction used the
primers 5′-GGGGGGCTAGCATGGGTGCCGCAGCAAGC-
3′ and 5′-CAAACAAAATGTAACATAGAAATCGGC-3′ and
the second reaction used the primers 5′-GGGAGATCTT-
CAGTTTTGCATATCCG-3′ and 5′-GCCGATTTCTATGTTA-
CATTTTGTTTG-3′. The underlined codon encodes the D35N
mutation. Each PCR reaction amplified part of the L1R gene.
The two PCR reactions, consisting of parts of the L1R gene
containing the mutation, were gel purified and a final PCR
reaction was performed by combining both PCR fragments and
the primers 5′-GGGGGGCTAGCATGGGTGCCGCAG-
CAAGC-3′ and 5′-GGGAGATCTTCAGTTTTGCATATCCG-
3′. These primers amplified the entire L1R coding region and
also introduced NheI and BglII sites into the product. The
resultant PCR product was digested with NheI and BglII (New
England Biolabs, Ipswich,MA) and then cloned into the pWRG/
TPA vector. The mutation to form pWRG/TPA-L1R D35N was
verified by DNA sequencing.
Flow cytometry
COS-7 cell monolayers (70–80% confluent) were transiently
transfected with pWRG/TPA-L1R, pWRG/TPA-L1R D35N, or
empty vector using Fugene6 (Roche, Indianapolis, IN) accord-
ing to the manufacturer's recommendations. Transfected cells
were incubated at 37 °C for 48 h, trypsinized, washed once with
EMEM, and 5×105 cells were transferred to 1.5-ml tubes. Cells
were incubated with the appropriate antibodies (1:100) for 1 h at
room temperature with continuous agitation. After incubation
with the primary antibody, cells were pelleted by centrifugation
at 750×g for 3 min and washed twice with PBS. Cells were next
incubated with anti-mouse Alexa 488 (Invitrogen, Carlsbad,
CA) (1:500) for 30 min at room temperature. After incubation
with the secondary antibody, cells were pelleted by centrifuga-
tion at 750×g for 3 min. Washed cells were resuspended in 1 ml
of FACS buffer. Flow cytometry was performed on a
FACSCalibur flow cytometer (Becton Dickinson, San Jose,
CA). Data were collected and analyzed using Cell Quest
software.
DNA cloning of the variable domains of 7D11
To obtain the sequence of the mAb-7D11 variable region,
RNAwas isolated from the hybridoma using Trizol according tothe manufacturer's instructions (Invitrogen, Carlsbad, CA).
First-strand DNA was synthesized from the RNA using the
Superscript III first-strand kit (Invitrogen, Carlsbad, CA). The
product was used as the template for 30 rounds of PCR. Both
primers used to PCR the light chain and the 3′ primer used for the
heavy chain were from the Novagen mouse Ig-Primer set (EMD
Biosciences, San Diego, CA). The 5′ heavy chain primers from
the Ig-Primer set did not produce a PCR product so the following
four 5′ primers were designed based on the results of N-terminal
protein sequencing of 7D11: 5′-CAGGTCCAGCTGCAGCA-
GTCTGGGGCTG-3′ (Primer HC-1), 5′-CAGCTGCAGCAGT-
CTGGGGCTGAACTGGC-3′ (Primer HC-2), 5′-GCAGTC-
TGGGGCTGAACTGGCAAAACCTGG-3′ (Primer HC-3),
and 5′-GGGGCTGAACTGGCAAAACCTGGGGC-3′ (Primer
HC-4). All four PCR reactions yielded products and the final
sequence was confirmed by at least two clones from each of the
four PCR products. The two plasmids containing the mAb-7D11
variable region heavy and light chains were designated pCR-
7D11-vHC and pCR-7D11-vLC, respectively.
Crystallization of the complex between L1 and 7D11-Fab
VACV L1 protein was expressed and purified as previously
described (Su et al., 2005). The purified L1 was mixed with
7D11-Fab in a 1:1 molar ratio with a final total protein concen-
tration of 8 mg/ml (∼120 μM). Crystals of the complex were
obtained by the hanging drop vapor diffusion method with 1 μl
of protein solution mixed with 1 μl of reservoir solution. The
best crystals were obtained by streak seeding with small crystals
using a reservoir solution of 0.1 M Tris–Cl pH 8.0 and 10–12%
PEG-10,000. The crystals were flash-frozen for data collection
in a solution containing 0.1 M Tris–Cl pH 8.0, 20% PEG-
10,000, and 20% glycerol.
Structure determination and analysis
X-ray data were collected, integrated, and scaled using the
HKL2000 software (Otwinowski and Minor, 1997). Models for
the variable and constant domains of the Fab (PDB code:
1YMH) (Granata et al., 2005) and a model of L1 (PDB code:
1YPY) (Su et al., 2005) were used as search models to determine
the structure by molecular replacement. The program PHASER
(McCoy et al., 2005) was used in a single search to position four
copies of the constant domains, then four copies of the variable
domains, and finally four copies of L1.
Iterative model building in O (Jones et al., 1991) based on
electron density maps, followed by refinement in Refmac
(Murshudov et al., 1997) and CNS (Adams et al., 1997) im-
proved the electron density and assignment of side-chain
rotamers. The variable regions of the Fab were rebuilt based
on the sequence obtained for 7D11. Non-crystallographic
symmetry restraints among the four copies of the L1:7D11-
Fab complex in the asymmetric unit were used during
refinement. Residues 2–3 and 177–185 at the termini of L1
were disordered in the structure and not built into the model.
Buried surface area calculations were performed using CNS
(Lee and Richards, 1971). Shape correlation statistics were cal-
340 H.-P. Su et al. / Virology 368 (2007) 331–341culated using SC (Lawrence and Colman, 1993). Figures were
generated using Pymol (DeLano, 2002). The coordinates of the
L1:7D11-Fab complex have been deposited in the Research
Collaboratory for Structural Bioinformatics protein data bank
(RCSB pdb code 2I9L).
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